Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Return on Sales (2016 - 2024)

Seres Therapeutics (MCRB) has disclosed Return on Sales for 9 consecutive years, with 0.95% as the latest value for Q3 2024.

  • Quarterly Return on Sales rose 2112.0% to 0.95% in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.95% through Sep 2024, down 69.0% year-over-year, with the annual reading at 9.34% for FY2022, 889.0% down from the prior year.
  • Return on Sales hit 0.95% in Q3 2024 for Seres Therapeutics, down from 0.22% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 52.61% in Q1 2024 to a low of 136.94% in Q1 2023.
  • Historically, Return on Sales has averaged 13.9% across 5 years, with a median of 3.71% in 2020.
  • Biggest five-year swings in Return on Sales: plummeted -9925bps in 2023 and later surged 18955bps in 2024.
  • Year by year, Return on Sales stood at 4.81% in 2020, then tumbled by -243bps to 6.88% in 2021, then soared by 67bps to 2.25% in 2022, then soared by 102bps to 0.05% in 2023, then crashed by -1928bps to 0.95% in 2024.
  • Business Quant data shows Return on Sales for MCRB at 0.95% in Q3 2024, 0.22% in Q2 2024, and 52.61% in Q1 2024.